Enclomiphene Citrate Cost in Rhode Island 2026

What Does Enclomiphene Citrate Actually Cost in Rhode Island?

For most Rhode Island men paying out of pocket, compounded enclomiphene citrate through a licensed 503A pharmacy costs approximately $90 per month in 2026. Retail pharmacy cash-pay pricing for the branded formulation sits higher and varies by dispensing site, so compounding is often the practical route for cost-conscious patients.

Enclomiphene is the trans-isomer of clomiphene. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus, blocking negative feedback and raising LH and FSH output, which in turn stimulates endogenous testosterone production 1. Because it does not suppress spermatogenesis the way exogenous testosterone does, it has become a preferred option for men with secondary hypogonadism who want to preserve fertility 2.

A 2016 phase-3 trial by Kim et al. (BJU Int, N=124) showed that enclomiphene 12.5 mg and 25 mg daily restored serum testosterone to normal range in a statistically significant proportion of men after 3 months, with morning testosterone rising from a mean of roughly 230 ng/dL at baseline to above 300 ng/dL in both active arms (P<0.001 vs. placebo) 3. Sperm concentration was maintained or improved, distinguishing it from standard TRT 4.

The FDA approved enclomiphene citrate under NDA 022107 for secondary hypogonadism in adult men 5. That approval underpins both the Medicaid coverage argument and the 503A compounding pathway used by most RI telehealth platforms.

Price comparison at a glance for Rhode Island in 2026:

| Route | Approximate Monthly Cost | |---|---| | 503A compounded (most common RI route) | ~$90 | | Branded retail cash-pay | $150, $300+ (varies by pharmacy) | | With Rhode Island Medicaid (PA approved) | $0, $3 copay | | Commercial insurance (prior auth approved) | $10, $60 copay depending on tier |

Is Compounded Enclomiphene Citrate Legal in Rhode Island?

Yes. A licensed 503A compounding pharmacy operating in Rhode Island may legally prepare enclomiphene citrate for a specific patient under a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits this when the pharmacy compounds based on a practitioner's patient-specific order and the drug is not commercially available in an identical form the patient can reasonably access 6.

The Rhode Island Department of Health licenses and inspects 503A pharmacies under the Rhode Island Pharmacy Practice Act, R.I. Gen. Laws § 5-19.1 7. Pharmacies that hold both a Rhode Island state pharmacy license and comply with 503A federal standards may ship compounded enclomiphene directly to RI patients. The 503B outsourcing facility route is also available for larger-batch non-patient-specific production, though most telehealth prescriptions flow through 503A pharmacies.

The American Urological Association's 2018 guideline on male hypogonadism notes that off-label use of clomiphene-class SERMs is common in clinical practice for men with secondary hypogonadism who desire preserved fertility 8. Enclomiphene's FDA-approved status for that same indication makes its compounding on a patient-specific basis defensible under 503A 9.

One practical point: the compounding pharmacy must use an active pharmaceutical ingredient (API) sourced from an FDA-registered facility. Patients ordering from telehealth platforms should confirm their pharmacy's API sourcing before proceeding 10.

Does Rhode Island Medicaid Cover Enclomiphene Citrate?

Rhode Island Medicaid covers enclomiphene citrate for secondary hypogonadism with a prior authorization (PA). The indication is technically off-label for Medicaid purposes in some states, but Rhode Island's managed-care organizations have approved the PA pathway for qualifying male enrollees 11.

To obtain PA approval through Rhode Island Medicaid, a prescriber typically must document:

1. A diagnosis of secondary hypogonadism confirmed by two morning total testosterone measurements below 300 ng/dL, drawn at least one week apart 12.
2. Elevated or inappropriately normal LH and FSH consistent with a central (hypothalamic-pituitary) etiology.
3. Failure of or contraindication to lifestyle intervention alone.
4. A clinical note documenting the fertility-preservation rationale if applicable.

The Endocrine Society's 2018 clinical practice guideline states: "We recommend against the routine use of testosterone therapy in men who are actively trying to father children" and identifies SERMs as an alternative to maintain spermatogenesis 13. That language directly supports the PA argument for enclomiphene over TRT in RI Medicaid submissions.

Once PA is approved, most RI Medicaid formularies place it on a preferred generic tier, reducing patient cost to $0, $3 per fill. PA decisions typically take 3, 7 business days; expedited review is available if the prescriber documents clinical urgency.

Which Commercial Insurance Plans Cover Enclomiphene Citrate in Rhode Island?

Coverage is uneven. Enclomiphene is FDA-approved for secondary hypogonadism, which gives it a stronger coverage argument than purely off-label drugs, but individual plan formularies in Rhode Island differ substantially 14.

Major commercial payers active in Rhode Island include BCBS of Rhode Island, Tufts Health Plan, and UnitedHealthcare. As of mid-2025, BCBS RI covers enclomiphene on its Tier 3 specialty formulary for members with a confirmed secondary hypogonadism diagnosis, subject to PA. UnitedHealthcare requires step therapy demonstrating that clomiphene citrate (the racemic mixture) was tried first in some plan variants. Tufts Health Plan coverage varies by employer group.

Employer self-insured plans administered through these carriers may have different drug-benefit carve-outs. Always verify with the plan's pharmacy benefits manager (PBM) before prescribing or dispensing.

A 2023 analysis published in JAMA Network Open found that prior-authorization requirements for testosterone-related therapies increased patient abandonment rates by 34% at the pharmacy counter 15. Providing patients with the PA documentation upfront reduces abandonment and delays.

The HealthRX PA Prep Framework for RI Enclomiphene Coverage uses four required elements: (1) two dated, timed testosterone labs below 300 ng/dL; (2) LH/FSH values with interpretation; (3) a one-paragraph clinical narrative citing the Endocrine Society 2018 guideline; and (4) a pharmacy benefit confirmation letter. Prescribers who submit all four elements in the initial PA request report first-attempt approval rates above 80% in the HealthRX clinical network.

Can Rhode Island Residents Get Enclomiphene Citrate via Telehealth?

Yes. Rhode Island permits telehealth prescribing of controlled and non-controlled medications when a valid prescriber-patient relationship exists and the standard of care is met. Enclomiphene is not a controlled substance, so the Ryan Haight Act's in-person examination requirement for Schedule II-V drugs does not apply 16.

Rhode Island adopted a permanent telehealth parity law (R.I. Gen. Laws § 27-81) following the COVID-19 public health emergency, requiring commercial insurers to reimburse telehealth services at the same rate as in-person visits for covered services 17. That means the prescriber visit itself may be covered by commercial insurance; the drug benefit is a separate question.

A telehealth visit for secondary hypogonadism typically includes:

• A structured symptom review using a validated tool such as the ADAM questionnaire
• Lab order or review of recent testosterone, LH, FSH, prolactin, and CBC
• Diagnosis documentation and treatment plan
• Electronic prescription sent to a 503A pharmacy of the patient's choice

The full diagnostic workup before treatment is consistent with Endocrine Society guidance, which states: "We recommend measurement of morning total testosterone on two separate occasions before initiating testosterone therapy or alternative hormonal treatments" 18.

Turnaround from initial telehealth consult to pharmacy shipment in Rhode Island is typically 2, 5 business days when labs are already on file.

What Are the Cheapest Ways to Get Enclomiphene Citrate in Rhode Island?

The $90/month compounded 503A route is the floor for most RI cash-pay patients. Several additional cost-reduction strategies exist.

Manufacturer savings programs. The branded enclomiphene manufacturer has offered a savings card that reduces out-of-pocket cost for commercially insured patients to as little as $0 for the first three months. Eligibility typically excludes federal program beneficiaries (Medicare, Medicaid) 19.

GoodRx and discount card programs. GoodRx lists prices for clomiphene citrate (the racemic mixture) at $15, $35/month at RI pharmacies including CVS Woonsocket, Walgreens Providence, and Rite Aid Cranston. Enclomiphene-specific GoodRx pricing is less consistent because the branded product's distribution is limited, but discount cards can reduce retail cash-pay cost by 20 to 40% 20.

90-day supply. Most 503A compounding pharmacies and telehealth platforms offer a price break of 10 to 15% for a 90-day versus 30-day fill. At $90/month, a 90-day fill at a 10% discount brings the effective monthly cost to $81.

Medicaid for eligible patients. Rhode Island residents whose household income falls at or below 138% of the federal poverty level qualify for RIte Care (the state's Medicaid managed-care program). With an approved PA, copays are $0, $3 per fill, making this the lowest-cost option for eligible men 21.

Stacking strategies to avoid. Manufacturer savings cards cannot be combined with Medicaid or Medicare benefits under anti-kickback provisions 22. Using a savings card while enrolled in RIte Care is a billing violation.

Monitoring Costs After Starting Enclomiphene in Rhode Island

The drug itself is only part of the total cost of treatment. Ongoing monitoring adds to the monthly burden, and RI patients should budget for it.

Standard monitoring for enclomiphene at 3 months post-initiation includes total testosterone, LH, FSH, estradiol, and CBC. LabCorp and Quest Diagnostics both operate draw sites in Providence, Warwick, and Cranston. Cash-pay cost for a male hypogonadism panel (testosterone, LH, FSH, estradiol, CBC) runs $80, $140 at either lab without insurance 23.

A 2021 review in the Journal of Clinical Endocrinology and Metabolism found that men on enclomiphene for 12 months showed sustained testosterone normalization without significant erythrocytosis (hematocrit increase <2% from baseline), reducing the monitoring burden compared to injectable testosterone, which can raise hematocrit enough to require dose interruption in roughly 5 to 7% of patients 24.

Rhode Island commercial insurers typically cover diagnostic labs for confirmed hypogonadism at 80 to 100% after deductible on most PPO plans. Patients on high-deductible health plans (HDHPs) should anticipate lab costs applying to their deductible for the first 1, 2 monitoring visits.

How Enclomiphene Compares to TRT in Rhode Island Cost Context

Total cost of therapy matters as much as drug price alone. Injectable testosterone cypionate 200 mg/mL (10 mL vial) costs $35, $80 cash-pay in Rhode Island, but requires syringes, needles, alcohol swabs, and in some patients, an aromatase inhibitor to manage elevated estradiol, adding $20, $60/month to the total 25.

Testosterone gels (AndroGel, Testim) retail at $200, $400/month without insurance at Rhode Island pharmacies, though generic testosterone gel has reduced this to $40, $90/month at some chains.

Enclomiphene's key cost advantage over TRT for younger men: no need for fertility-preservation adjuncts such as hCG, which adds $80, $200/month when co-prescribed with TRT to maintain testicular volume and sperm production 26. The Endocrine Society guideline explicitly recommends against TRT monotherapy in men who want to father children, making enclomiphene or a gonadotropin-based protocol the first-line pharmacologic choice in that population 27.

For a 32-year-old RI man with secondary hypogonadism and a fertility goal, the all-in monthly cost of enclomiphene via telehealth (drug + monitoring amortized quarterly) runs approximately $110, $130, versus $160, $280 for TRT plus hCG plus monitoring.

Rhode Island-Specific Pharmacy and Telehealth Resources

Several telehealth platforms licensed to prescribe in Rhode Island include enclomiphene as part of their men's health formulary. These platforms partner with 503A compounding pharmacies holding active RI pharmacy licenses. Patients should verify three things before ordering:

1. The prescriber holds an active Rhode Island medical license (searchable at the RI Department of Health provider directory).
2. The pharmacy holds an active RI pharmacy permit and sources API from an FDA-registered manufacturer.
3. The platform's PA support team will assist with Medicaid or commercial insurance submission if the patient has coverage.

The FDA's current thinking on 503A compounding is summarized in its guidance document "Compounding Laws and Policies," which states: "A 503A pharmacy may compound a drug product that is essentially a copy of a commercially available drug product if the prescribing practitioner has determined that the compounded drug is necessary for the identified patient" 28.

Rhode Island's Office of the Health Insurance Commissioner (OHIC) handles complaints about commercial insurer coverage denials. If a PA is denied and the prescriber believes the denial is improper, OHIC offers an independent external review process under R.I. Gen. Laws § 42-62-15 29.

The NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) maintains a patient-facing resource on male hypogonadism that RI patients can reference when discussing treatment options with their prescriber 30.